Clobazam: In patients with Lennox-Gastaut syndrome

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 983-991

  Yang, Lily P H ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; CAFFEINE; CARBAMAZEPINE; CLOBAZAM; CONTRACEPTIVE AGENT; DEXTROMETHORPHAN; DIAZEPAM; ESLICARBAZEPINE; FELBAMATE; FLUCONAZOLE; FLUVOXAMINE; KETOCONAZOLE; LAMOTRIGINE; MIDAZOLAM; NORCLOBAZAM; OMEPRAZOLE; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PLACEBO; TICLOPIDINE; TOLBUTAMIDE; UNCLASSIFIED DRUG; URBANOL;

AGGRESSION; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CENTRAL NERVOUS SYSTEM DEPRESSION; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FATIGUE; FEVER; HUMAN; HYPERSALIVATION; INSOMNIA; IRRITABILITY; LENNOX GASTAUT SYNDROME; LETHARGY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYOCLONUS EPILEPSY; PNEUMONIA; PRIORITY JOURNAL; QT INTERVAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEADY STATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TONIC CLONIC SEIZURE; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ANTICONVULSANTS; BENZODIAZEPINES; BIOLOGICAL AVAILABILITY; HUMANS; INTELLECTUAL DISABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPASMS, INFANTILE; TREATMENT OUTCOME;

EID: 84873435471     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0007-0     Document Type: Article

References (29)

1. Arzimanoglou A, Resnick T. All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome. but many do. Epileptic Disord. 2011;13(Suppl 1):S3-13.
2. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93.
3. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatri Dis Treat. 2008;4(6):1001-19.
4. Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf. 2000;22(6):467-77.
5. Hancock EC, Cross HJ. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009; (4): CD003277.
6. Montouris GD. Rational approach to treatment options for Lennox-Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):10-20.
7. Crumrine PK. Management of seizures in Lennox-Gastaut syndrome. Paediatr Drugs. 2011;13(2):107-18.
8. Gallop K, Wild D, Nixon A, et al. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8):554-8.
9. Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69-86.
10. Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26(3):229-44.
11. National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (NICE clinical guideline 137). http://www.nice.org.uk/ nicemedia/live/13635/57779/57779.pdf. Accessed 24 Jul 2012.
12. Sanofi Aventis. Frisium™ (clobazam) 10 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/8298/SPC/ Frisium+Tablets+10+mg/. Accessed 23 Jul 2012.
13. Ng Y-T, Collins SD. Clobazam. Neurotherapeutics. 2007;4(1):138-44.
14. Lunbeck Inc. Onfi™ (clobazam) oral tablets: US prescribing information. http://www.lundbeck.com/upload/us/files/pdf/Products/Onfi-PI-US-EN. pdf. Accessed 2 Aug 2012.
15. Jensen HS, Ebert B. Clobazam and its active metabolite, N-desmethylclobazam, are high-affinity ligands for the benzodiazepine sites of GABAA receptors [abstract no. P05.086]. Neurology. 2012;78 Suppl 1.
16. Löscher W, Schmidt D. Experimental and clinical evidence of loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47(8):1253-84.
17. Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia. 1998;39(9):952-9.
18. Hussein Z, Ferry J, Krauss G, et al. Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel [abstract no. P06.127]. Neurology. 2012;78 Suppl 1.
19. Falcão A, Fuseau E, Nunes T, et al. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. CNS Drugs. 2012;26(1):79-91.
20. Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-53.
21. Volz M, Christ O, Kellner HM, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7(Suppl 1):41S-50S.
22. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7(Suppl 1):51S-7S.
23. Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32(11):1279-86.
24. Renfroe J, Conry J, Ng Y-T, et al. Effects of concomitant lamotrigine or valproate therapy on clobazam for Lennox-Gastaut syndrome: subanalyses of the CONTAIN trial [abstract no. P06.120]. Neurology 2012;78 Suppl 1.
25. Mitchell W, Conry J, Ng Y-T, et al. Clobazam is efficacious for drop attacks in patients with Lennox-Gastaut syndrome across the age spectrum: subgroup analysis of the CONTAIN trial [abstract no. P06.096]. Neurology 2012;78 Suppl 1.
26. Ng Y-T, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77 (15): 1473-81. http://www.neurology.com. Accessed 24 Jul 2012.
27. Conry JA, Ng Y-T, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158-66.
28. Ng Y-T, Conry JA, Paolicchi JM, et al. Long-term safety and efficacy of clobazam for Lennox Gastaut syndrome (LGS): 2-year results of an open label extension (OLE) study [abstract no. 14]. Ann Neurol. 2011;70(Suppl 1):S15-140.
29. Tolbert D, Harris S, Bekersky I, et al. Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome (LGS) [abstract no. P06.106]. Neurology 2012; 78 (Suppl 1).